Fox Run Management L.L.C. Buys Shares of 16,667 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Fox Run Management L.L.C. purchased a new position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 16,667 shares of the biopharmaceutical company’s stock, valued at approximately $1,392,000.

A number of other institutional investors also recently modified their holdings of ITCI. Wasatch Advisors LP lifted its holdings in Intra-Cellular Therapies by 3.5% in the third quarter. Wasatch Advisors LP now owns 3,848,588 shares of the biopharmaceutical company’s stock valued at $281,601,000 after buying an additional 130,351 shares during the period. Bellevue Group AG lifted its stake in shares of Intra-Cellular Therapies by 0.6% in the 3rd quarter. Bellevue Group AG now owns 2,485,627 shares of the biopharmaceutical company’s stock valued at $181,873,000 after purchasing an additional 14,342 shares during the period. State Street Corp boosted its position in shares of Intra-Cellular Therapies by 3.1% during the 3rd quarter. State Street Corp now owns 1,858,915 shares of the biopharmaceutical company’s stock valued at $136,017,000 after purchasing an additional 56,664 shares in the last quarter. Franklin Resources Inc. grew its stake in Intra-Cellular Therapies by 9.7% during the third quarter. Franklin Resources Inc. now owns 1,753,286 shares of the biopharmaceutical company’s stock worth $129,463,000 after purchasing an additional 155,655 shares during the period. Finally, Geode Capital Management LLC increased its holdings in Intra-Cellular Therapies by 1.3% in the third quarter. Geode Capital Management LLC now owns 1,708,301 shares of the biopharmaceutical company’s stock worth $125,029,000 after purchasing an additional 22,128 shares in the last quarter. 92.33% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Baird R W cut Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Canaccord Genuity Group cut shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and raised their price target for the stock from $119.00 to $132.00 in a report on Friday, January 31st. Needham & Company LLC reaffirmed a “hold” rating on shares of Intra-Cellular Therapies in a research note on Friday, February 21st. Royal Bank of Canada reissued a “sector perform” rating and set a $132.00 price objective (up previously from $108.00) on shares of Intra-Cellular Therapies in a research report on Wednesday, January 22nd. Finally, Leerink Partnrs lowered Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Ten equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Intra-Cellular Therapies presently has a consensus rating of “Hold” and an average price target of $106.08.

Intra-Cellular Therapies Trading Up 0.0 %

NASDAQ ITCI opened at $131.65 on Friday. The business has a fifty day simple moving average of $128.61 and a 200 day simple moving average of $97.41. Intra-Cellular Therapies, Inc. has a 12 month low of $64.09 and a 12 month high of $131.67. The firm has a market capitalization of $14.00 billion, a P/E ratio of -151.32 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The firm had revenue of $199.22 million during the quarter, compared to analysts’ expectations of $205.08 million. As a group, sell-side analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.